Working... Menu

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02371980
Recruitment Status : Active, not recruiting
First Posted : February 26, 2015
Last Update Posted : June 21, 2018
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with major depressive disorder (MDD) who responded to acute treatment with vortioxetine 10 mg.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: Vortioxetine Drug: Placebo Phase 4

Detailed Description:

The drug being tested in this study is called vortioxetine. Vortioxetine is being tested for the prevention of relapse in adults with major depressive disorder (MDD) who respond to daily treatment with vortioxetine. This study will look at relapse rates of MDD in people who take vortioxetine.

The study will enroll approximately 1100 participants. All participants will receive vortioxetine 10 mg open-label for the first 16 weeks of the study. Participants who meet the appropriate MDD response criteria from the Week 8 Visit through Week 16 Visit will be eligible for randomization into the double-blind treatment period. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups—which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Vortioxetine 5 mg
  • Vortioxetine 10 mg
  • Vortioxetine 20 mg
  • Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient

All participants will be asked to take one capsule at the same time each day throughout the study.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 55 weeks. Participants will make 19 visits to the clinic, and will be contacted by telephone 4 weeks after last dose of study drug for a follow-up assessment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1107 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder
Actual Study Start Date : February 18, 2015
Estimated Primary Completion Date : May 1, 2019
Estimated Study Completion Date : May 1, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Open-label: Vortioxetine 10 mg
Vortioxetine 10 mg, capsules, orally, once, daily Week 1 through Week 16.
Drug: Vortioxetine
Vortioxetine capsules
Other Name: LuAA21004

Experimental: Double-blind: Vortioxetine 5 mg
Vortioxetine 5 mg, capsules, orally, once, daily, Week 17 through Week 44.
Drug: Vortioxetine
Vortioxetine capsules
Other Name: LuAA21004

Experimental: Double-blind: Vortioxetine 10 mg
Vortioxetine 10 mg, capsules, orally, once, daily, Week 17 through Week 44.
Drug: Vortioxetine
Vortioxetine capsules
Other Name: LuAA21004

Experimental: Double-blind: Vortioxetine 20 mg
Vortioxetine 20 mg, capsules, orally, once, daily, Week 17 through Week 44.
Drug: Vortioxetine
Vortioxetine capsules
Other Name: LuAA21004

Placebo Comparator: Double-blind: Placebo
Vortioxetine placebo-matching capsules, orally, once, daily, Week 17 through Week 44.
Drug: Placebo
Vortioxetine placebo-matching capsules

Primary Outcome Measures :
  1. Time from Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period [ Time Frame: From date of double-blind randomization (Week 16) to relapse (up to Week 44) ]
    Relapse is defined as depression (Montgomery-Åsberg Depression Rating Scale MADRS Score ≥22), or lack of efficacy as determined by the investigator.

Secondary Outcome Measures :
  1. Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score [ Time Frame: Double-blind Baseline (Week 16) and Weeks 18, 20, 24, 28, 32, 36, 40, 44 and 48 ]
    The change between MADRS total score at each week assessed or final visit and MADRS score at baseline in the double-blind period. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.

  2. Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Each Week Assessed [ Time Frame: Double-blind Baseline (Week 16) and Weeks 18, 20, 24, 28, 32, 36, 40, 44 and 48 ]
    The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

  3. Clinical Global Impression Scale-Global Improvement Scale (CGI-I) score at Each Week Assessed in the double-blind period [ Time Frame: Weeks 18, 20, 24, 28, 32, 36, 40, 44 and 48 ]
    The CGI-I scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.

  4. Time from Randomization to Relapse of Major Depressive Disorder During the entire 32-Week Double-Blind Treatment Period [ Time Frame: From date of double-blind randomization (Week 16) to relapse (up to Week 48) ]
    Relapse is defined as depression (Montgomery-Asberg Depression Rating Scale (MADRS Score ≥22), or lack of efficacy as determined by the investigator.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. Suffers from recurrent major depressive disorder (MDD) as the primary diagnosis according to Diagnostic & Statistical Manual of Mental Disorders, 4th Edition - Text Revision (DSM-IV-TR) criteria (classification code 296.3x), and the current episode is confirmed by the Mini International Neuropsychiatric Interview (MINI).
  4. Reported duration of the current episode is ≥8 weeks and ≤18months.
  5. Had at least 2 other major depressive episodes (MDEs) before the current episode.
  6. Has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥26 at the Screening and Baseline I visits.
  7. Is a man or woman aged 18 to 75 years, inclusive.
  8. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to routinely use adequate contraception from signing of the informed consent throughout the duration of the study and for 30 days after the last dose.

Exclusion Criteria:

  1. Has received any investigational compound within 30 days prior to screening or 5 half-lives prior to screening, whichever is longer.
  2. Has previously or is currently participating in this study.
  3. Has participated in 2 or more clinical studies in the year prior to screening, or has participated in a clinical trial for a psychiatric condition that is exclusionary per this protocol.
  4. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  5. Has one or more of the following:

    1. Any current psychiatric disorder which is the primary focus of treatment other than MDD as defined in the DSM-IV-TR, and assessed by the MINI.
    2. Current or history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features, obsessive compulsive disorder (OCD), mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    3. Current diagnosis or history of alcohol or other substance abuse or dependence (excluding nicotine or caffeine) as defined in the DSM-IV-TR that has not been in full and sustained remission for at least 3 months from the day of screening (Participant must also have negative urine drug screen at Screening and Baseline I.)
    4. Presence or history of a clinically significant neurological disorder (including epilepsy) as determined by the investigator.
    5. Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
    6. Any Axis II disorder as defined by DSM-IV-TR that might compromise the study.
  6. The current depressive symptoms of the participant are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each.
  7. Has a history of lack of response to previous adequate treatment with vortioxetine for any MDD episode with adequate treatment considered to be known dose of vortioxetine in the approved recommended dose range for at least 6 weeks duration.
  8. Has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening.
  9. Has started receiving formal cognitive or behavioral therapy, systematic psychotherapy within 30 days from screening or plans to initiate such therapy during the study (supportive therapy, marital therapy and bereavement counseling are allowed).
  10. Has a significant risk of suicide according to the investigator's clinical judgment or has a score ≥5 on item 10 (suicidal thoughts) of the MADRS or has made a suicide attempt in the previous 6 months.
  11. Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study.
  12. Has a clinically significant unstable illness, for example hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, hematological, infectious, dermatological disorder or metabolic disturbance.

    Note: For the purposes of this protocol fibromyalgia, obstructive sleep apnea, chronic pain diagnosis, and morbid obesity (BMI of > 40) are considered unstable due to the potential impact on assessment of the primary endpoint.

  13. Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.
  14. Has 1 or more laboratory value outside the normal range, based on the blood or urine samples taken at the Screening Visit, that are considered by the investigator to be clinically significant; or the participant has any of the following values at the Screening Visit:

    1. A serum creatinine value >1.5 times the upper limits of normal (ULN).
    2. A serum total bilirubin value >1.5 xULN.
    3. A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >2 xULN.
  15. Has glycosylated hemoglobin (HbA1C) ≥7% at screening and no prior diagnosis of diabetes and/or treatment for diabetes. NOTE: Participants with known stable diabetes are not excluded.
  16. Has a thyroid stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator. NOTE: Free T4 will be checked if TSH is out of range. If free T4 is abnormal the participant will be excluded.
  17. Has clinically significant abnormal vital signs as determined by the investigator.
  18. Has an abnormal electrocardiogram (ECG) as determined by the central reader and confirmed as clinically significant by the investigator.
  19. Is positive for Hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, or has a history of human immunodeficiency virus (HIV) infection.
  20. Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability or efficacy.
  21. The participant, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
  22. Has a history of hypersensitivity or allergies to vortioxetine.
  23. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  24. The subject is considered to be treatment resistant, eg, the subject has not responded to adequate monotherapy treatments of at least 6 weeks' duration, or has only responded to combination or augmentation therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02371980

  Hide Study Locations
Layout table for location information
United States, Arizona
Phoenix, Arizona, United States, 85032
SW Biomedical Research, LLC
Tucson, Arizona, United States, 85712
United States, California
CNS Research Science, Inc.
Cerritos, California, United States, 90703
Collaborative Neuroscience Network, LLC
Garden Grove, California, United States, 92845
Irvine Center for Clinical Research, Inc.
Irvine, California, United States, 92614
Synergy Clinical Research of Escondido
Lemon Grove, California, United States, 91945
Pharmacology Research Institute
Los Alamitos, California, United States, 90720
Pacific Institute of Medical Research
Los Angeles, California, United States, 90024
CNRI - Los Angeles, LLC
Pico Rivera, California, United States, 90660
CNRI - San Diego, LLC
San Diego, California, United States, 92102
Artemis Institute for Clinical Research, LLC
San Diego, California, United States, 92103
University of California San Diego Medical Center
San Diego, California, United States, 92103
Pasadena Research Institute
San Gabriel, California, United States, 91776
Collaborative Neuroscience Network, LLC
Torrance, California, United States, 90502
United States, Connecticut
Research Center for Clinical Studies, Inc.
Norwalk, Connecticut, United States, 06851
United States, Florida
CNS Clinical Research Group
Coral Springs, Florida, United States, 33067
Gulfcoast Medical Research Center, LLC
Fort Myers, Florida, United States, 33912
MD Clinical
Hallandale Beach, Florida, United States, 33009
Indago Research & Health Center, Inc.
Hialeah, Florida, United States, 33012
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States, 32256
Meridien Research
Maitland, Florida, United States, 32751
Sarkis Clinical Trials - Parent
Ocala, Florida, United States, 34474
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States, 32801
Stedman Clinical Trials, LLC
Tampa, Florida, United States, 33613
Janice L. Miller, M.D., PA d/b/a Janus Center for Psychiatric Reseach
West Palm Beach, Florida, United States, 33407
United States, Georgia
Radiant Research, Inc.
Atlanta, Georgia, United States, 30328
Atlanta Center for Medical Research
Atlanta, Georgia, United States, 30331
iResearch Atlanta, LLC
Decatur, Georgia, United States, 30030
United States, Illinois
Alexian Brothers Center for Psychiatric Research
Arlington Heights, Illinois, United States, 60005
Rush St Lukes Presbyterian Medical Center
Chicago, Illinois, United States, 60612
Capstone Clinical Research, Inc.
Libertyville, Illinois, United States, 60048
United States, Indiana
Goldpoint Clinical Research, LLC
Indianapolis, Indiana, United States, 46260
Buynak Clinical Research
Valparaiso, Indiana, United States, 46383
United States, Kansas
Phoenix Medical Research, Inc.
Prairie Village, Kansas, United States, 66208
Heartland Research Associates, LLC
Wichita, Kansas, United States, 67207
United States, Louisiana
Lake Charles Clinical Trials, LLC
Lake Charles, Louisiana, United States, 70629
United States, Maryland
Pharmasite Research, Inc.
Baltimore, Maryland, United States, 21208
Potomac Grove Clinical Research Center
Gaithersburg, Maryland, United States, 20877
United States, Massachusetts
Boston Clinical Trials & Medical Research
Boston, Massachusetts, United States, 02131
Univ. of Massachussetts Memorial Health Care Systems
Worcester, Massachusetts, United States, 01605-2610
United States, Nevada
Altea Research Institute
Las Vegas, Nevada, United States, 89102
United States, New Jersey
Hassman Research Institute
Berlin, New Jersey, United States, 08009
United States, New York
Montefiore Medical Center PRIME
Bronx, New York, United States, 10467
Erie County Medical Center Corporation
Buffalo, New York, United States, 14215
Neurobehavioral Research, Inc.
Cedarhurst, New York, United States, 11516
CNS Research Science, Inc.
Jamaica, New York, United States, 11432
Village Clinical Research, Inc.
New York, New York, United States, 10003
Manhattan Behavioral Medicine, PLLC
New York, New York, United States, 10022
Finger Lakes Clinical Research
Rochester, New York, United States, 14618
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Clinical Trials of America, Inc
Hickory, North Carolina, United States, 28601
United States, Ohio
NorthCoast Clinical Trials, Inc.
Beachwood, Ohio, United States, 44122
Patient Priority Clinical Sites, LLC
Cincinnati, Ohio, United States, 45215
United States, Oklahoma
IPS Research Company
Oklahoma City, Oklahoma, United States, 73103
Cutting Edge Research Group, Inc.
Oklahoma City, Oklahoma, United States, 73116
United States, Oregon
Summit Research Network (Oregon) Inc.
Portland, Oregon, United States, 97210
Oregon Center for Clinical Investigations, Inc.
Portland, Oregon, United States, 97214
United States, Pennsylvania
Suburban Research Associates
Media, Pennsylvania, United States, 19063
Keystone Clinical Studies, LLC
Norristown, Pennsylvania, United States, 19403
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, United States, 19104
United States, Rhode Island
Lincoln Research
Lincoln, Rhode Island, United States, 02865
United States, South Carolina
Medical University of South Carolina (MUSC)
Charleston, South Carolina, United States, 29401
Coastal Carolina Research Center, Inc
Mount Pleasant, South Carolina, United States, 29464
United States, Tennessee
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, United States, 38119
United States, Texas
FutureSearch Clinical Trials, L.P.
Austin, Texas, United States, 78731
BioBehavioral Research of Austin
Austin, Texas, United States, 78759
FutureSearch Trials of Dallas, LP
Dallas, Texas, United States, 75231
Bayou City Research, Ltd.
Houston, Texas, United States, 77007
Houston Clinical Trials, LLC
Houston, Texas, United States, 77098
Pillar Clinical Research, LLC
Richardson, Texas, United States, 75080
Clinical Trials of Texas, Inc.
San Antonio, Texas, United States, 78229
United States, Utah
Radiant Research, Inc.
Murray, Utah, United States, 84123
United States, Vermont
Neuropsychiatric Associates
Woodstock, Vermont, United States, 05091
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22903
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States, 23298-5054
United States, Washington
Eastside Therapeutic Resource
Everett, Washington, United States, 98201
Summit Research Network (Seattle), LLC
Seattle, Washington, United States, 98104
Frontier Institute
Spokane, Washington, United States, 99204
United States, Wisconsin
Northbrooke Research Center
Brown Deer, Wisconsin, United States, 53223
Sponsors and Collaborators
Layout table for investigator information
Study Director: Medical Director Clinical Science Takeda

Layout table for additonal information
Responsible Party: Takeda Identifier: NCT02371980     History of Changes
Other Study ID Numbers: LuAA21004_402
U1111-1161-4956 ( Registry Identifier: WHO )
First Posted: February 26, 2015    Key Record Dates
Last Update Posted: June 21, 2018
Last Verified: June 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Takeda:
Drug therapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Antidepressive Agents
Psychotropic Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin 5-HT3 Receptor Antagonists
Serotonin Antagonists